sitefansalaran International News

 UAE-developed artificial intelligence technology is breaking new ground in American health care, with the open-source Falcon Large Language Model (LLM) being deployed to tackle language barriers for nearly 200,000 Arabic-speaking patients in Michigan. The initiative represents the first major US deployment of the UAE’s advanced AI capabilities in health care applications. Velatura Public Benefit Corporation (Velatura), in partnership with J&B Medical, will unveil the initiative at the Caroline Kennedy Library in Dearborn on Sept. 18. The technology uses the UAE-developed open-source Falcon LLM to provide Arabic-English health care interactions for Dearborn's Arabic speakers—the largest such population in the Western Hemisphere. The deployment represents a significant milestone for UAE's AI leadership globally, showcasing how Emirati-developed technology is addressing real-world health care challenges internationally. The initiative positions the UAE as a key player in global health AI innovation while preparing to bring the refined technology back to serve UAE citizens and residents across the Gulf region. The company's products, including the Arabic edition of Consent Manager+™ and the Velatura Intellibot™ operating system, represent a new category of multilingual Arabic-English AI products designed for health care applications. These solutions go beyond traditional translation, incorporating Reinforcement Learning with Human Feedback to deliver culturally authentic interactions for Arabic-speaking communities. "This technology creates...

The Global Diabetes Drugs Market is expected to reach at a CAGR of 7.8% during the forecast period 2025-2032. The Global Diabetes Drugs Market is experiencing strong growth due to the rising prevalence of diabetes, advancements in pharmaceutical innovation, and increasing adoption of effective treatment therapies. According to DataM Intelligence, The Global Diabetes Drugs Market was valued at US$ 78.11 billion in 2024 and is projected to reach US$ 141.73 billion by 2032, expanding at a CAGR of 7.8% during 2025–2032. The demand is largely driven by growing patient awareness, government initiatives, and improved drug accessibility across both developed and emerging economies. A Major growth driver is the surge in Type 2 diabetes cases caused by sedentary lifestyles, obesity, and aging populations. Among drug categories, insulin and oral antidiabetic drugs dominate due to their wide prescription base and effectiveness. Geographically, North America dominates the market because of its sophisticated healthcare infrastructure, high awareness, and strong R&D presence. Asia-Pacific, however, is emerging as the fastest-growing region with increasing healthcare investments, large patient populations, and supportive government policies. Key Highlights from the Report: Rising prevalence of Type 2 diabetes is fueling demand for innovative drug therapies. Insulin analogs remain the leading product category in the diabetes drugs market. North...

King Faisal Specialist Hospital & Research Centre (KFSHRC) has witnessed a growing turnout of blood donors since the launch of the national campaign initiated by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister – may Allah protect him – reflecting the direct impact of this generous initiative and its role in fostering a culture of voluntary blood donation among members of society. As part of its efforts to broaden community participation in blood donation, KFSHRC’s Blood Bank in Riyadh organizes field campaigns in collaboration with various public and private sector entities to facilitate donor access and strengthen the culture of giving. These efforts have seen a remarkable increase following the campaign’s launch, underscoring the growing role of institutions in promoting voluntary donations to support the sustainability of national health security. KFSHRC is one of the largest tertiary care hospitals, requiring a steady supply of blood units and components, particularly for organ transplantation, cancer treatment, and complex surgeries. This highlights the vital importance of voluntary blood donation in enabling the hospital to save lives and enhance national health security. The national campaign aims to raise awareness about the importance of voluntary blood donation, achieve self-sufficiency...

Hanmi Pharmaceutical has officially announced its entry into the Middle Eastern market with its biosimilar drug ‘Rolontis’, used for treating neutropenia. On the 8th, Hanmi Pharmaceutical disclosed that it had signed a supply agreement for Rolontis with Tabuk Pharmaceuticals, a leading pharmaceutical company in Saudi Arabia. This agreement expands on the partnership established in October last year, with both companies set to collaborate on introducing Rolontis to the Middle Eastern market. Jae-hyun Park, CEO of Hanmi Pharmaceutical, attended the International Pharmaceutical and Biotech Exhibition (CPHI Middle East 2024) held in Riyadh, Saudi Arabia last year, where he strengthened cooperative relations with Tabuk’s CEO Ismail Shehada and Chief Business Officer Wisam Al Khatib. Tabuk, leveraging its market experience and expertise in the Middle East and North Africa (MENA) region, will play a crucial role in ensuring Rolontis’ stable entry into the regional market. The MENA region represents an extensive market with approximately 600 million residents. Saudi Arabia, in particular, is experiencing an expanding pharmaceutical market based on its high income levels. Tabuk is a leading pharmaceutical company with sales networks in 17 countries across the Middle East and North Africa. Rolontis, an anticancer biosimilar drug developed in-house by Hanmi Pharmaceutical, was the first...

The World Health Organization on Sunday called for the "protection of public health excellence" at the U.S. Centers for Disease Control and Prevention. "No institution is perfect and continued improvements are always needed to make sure the latest science and evidence is applied to emerging challenges in real time, but the work of the US CDC has been invaluable and must be protected," WHO Director General Tedros Adhanom Ghebreyesus said in a post on X. His comments come amid leadership changes at the CDC and concerns that decisions by U.S. Health Secretary Robert F. Kennedy Jr. are putting Americans' health at risk. Ghebreyesus did not echo those concerns or calls by some for Kennedy to resign. He instead pointed to how the CDC's reputation as a "center of excellence" has inspired other countries to adopt its best practices. Ghebreyesus said the WHO's longtime relationship with the CDC has ensured that people in the United States and around the world benefited from the best U.S. science "while at the same time providing the U.S. with access to global health data, alerts, experience and guidance from other countries." The Trump administration has been critical of the WHO for its handling of COVID-19, with Kennedy dismissing the...

The prestigious honor recognizes Mikhael’s exceptional leadership, commitment to advancing patient care, and significant contributions to the pharmaceutical industry across Florida Recognized for his leadership in advancing compounding, championing patient access, and shaping the future of pharmacy, Mark Mikhael, PharmD, CEO of Olympia and Wesley Pharmaceuticals, has been named Pharmacist of the Year by the Florida Society of Health-System Pharmacists (FSHP). This honor recognizes exceptional vision, professional excellence, and a steadfast commitment to improving healthcare for communities across Florida and beyond. Under Mikhael’s guidance, Olympia and Wesley Pharmaceuticals, two of the nation’s leading compound pharmacies, have expanded access to high-quality medications while driving industry-wide conversations about affordability and innovation in patient care. His advocacy extends beyond the boardroom, with a deep commitment to ensuring compounding remains a vital part of modern medicine. "It is a tremendous honor to be recognized by FSHP with this award," said Mikhael. "This achievement reflects the dedication of our entire team, whose passion for compounding and patient care inspires me daily. We remain committed to breaking down barriers so patients can access the medication they need, when they need it." Throughout his career, Mikhael has served as a bridge between policymakers, providers, and patients, helping to shape regulations...

 India is seeking to boost drug exports to semi-regulated markets in Africa, Latin America and Southeast Asia to reduce its dependence on the U.S., where tariff concerns pose risks, officials from a government-backed trade body told Reuters on Thursday. The Pharmaceuticals Export Promotion Council of India (Pharmexcil) also plans to push for sales of finished goods to China to bridge the trade deficit, the officials said. The Indian industry imports more than 60% of its raw materials and active pharmaceutical ingredients from China. Get the latest news from India and how it matters to the world with the Reuters India File newsletter. Sign up here. While Indian pharmaceutical exports are currently exempt from President Donald Trump's tariffs of up to 50%, growing uncertainty and tensions between the countries have kept the industry cautious. "It is a matter of concern for us," Pharmexcil Chairman Namit Joshi said, referring to the U.S. tariffs. The U.S. is India's largest market and accounts for slightly more than a third of India's pharmaceutical exports, which comprise mainly cheaper generic versions of popular drugs. Exports to the country rose 20% to about $10.5 billion in fiscal 2025. "The point is how medium and small enterprises and big companies can come together and work on those...

 Democrats and Republicans pushed U.S. Health Secretary Robert F. Kennedy Jr. on his recent vaccine policies and their stark contrast to President Donald Trump's successful first-term pandemic initiative to speed vaccine development during a combative Senate hearing on Thursday. Half a dozen heated exchanges focused on the details of Kennedy's decision to fire Centers for Disease Control and Prevention Director Susan Monarez, who had started the job with Kennedy's support only a month earlier. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Trump, speaking at the White House after the hearing, expressed support for Kennedy, saying he has some "different ideas." Republican Senator Bill Cassidy, a physician who played a critical role in Kennedy's confirmation, grilled him about the cancellation of $500 million in COVID vaccine contracts, while citing examples of doctors and cancer patients who have been unable to obtain the protection against the potentially deadly disease. "I would say, effectively, we're denying people vaccines," concluded Cassidy. "Well, you're wrong," Kennedy responded. Cassidy, of Louisiana, praised Trump for having accelerated the development, manufacturing, and distribution of COVID-19 vaccines in 2020. His line of questioning - mirrored by two other members of his and Trump's party - underscored the tightrope Republicans critical...

New York Governor Kathy Hochul signed an executive order on Friday authorizing pharmacists in the state to administer COVID-19 vaccinations to anyone who wants a shot, becoming the latest Democratic governor to try to countermand the Trump administration’s new limits on inoculations. The order, which Hochul signed during a visit to an elementary school, is effective for 30 days, though the governor said she would extend it as needed until the state legislature meets in January and can consider a more permanent fix. “If you want your child to have a COVID shot, it should be available to you and covered by insurance,” she said. “Extreme times call for extreme measures.” Under the leadership of U.S. Health Secretary Robert F. Kennedy Jr., a vaccine skeptic, the U.S. Food and Drug Administration has approved new versions of the COVID vaccine only for Americans over 65 or those with certain underlying medical conditions. In past years, the shots have generally been available to anyone. A spokesperson for CVS Health (CVS.N), opens new tab, which owns one of the largest pharmacy chains in the country, said it would "ensure COVID-19 vaccinations are available as soon as possible at all New York CVS Pharmacy locations" in accordance...

BURLINGAME, CA, UNITED STATES, August 29, 2025 /EINPresswire.com/ -- The Pharmaceutical Logistics Market : A thorough analysis of statistics about the current as well as emerging trends offers clarity regarding the Pharmaceutical Logistics Market dynamics. The report includes Porter's Five Forces to analyze the prominence of various features such as the understanding of both the suppliers and customers, risks posed by various agents, the strength of competition, and promising emerging businesspersons to understand a valuable resource. Also, the report spans the Pharmaceutical Logistics research data of various companies, benefits, gross margin, strategic decisions of the worldwide market, and more through tables, charts, and infographics. The Pharmaceutical Logistics Market report highlights an all-inclusive assessment of the revenue generated by the various segments across different regions for the forecast period, 2025 to 2032. To leverage business owners, and gain a thorough understanding of the current momentum, the Pharmaceutical Logistics Market research taps hard-to-find data on aspects including but not limited to demand and supply, distribution channel, and technology upgrades. Principally, the determination of strict government policies and regulations and government initiatives building the growth of the Pharmaceutical Logistics market offers knowledge of what is in store for business owners in the upcoming years.